Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

About this update from Shanghai Junshi Biosciences Co., Ltd. Class A

[{"type":"image","alt":"Junshi Biosciences","displaySize":"","headline":null,"caption":"Junshi Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4euD1KvxSTvPpofaq76LRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc","width":150,"height":56}},"lazy":false},{"type":"text","content":"SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study (study number: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis. Both the co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements. Junshi Biosciences plans to submit the new drug application of this product to the regulatory authorities in the near future.","length":866,"tagName":"p"},{"type":"text","content":"Psoriasis is a common chronic, recurrent, inflammatory, and systemic disease mediated by the immune system. Its prevalence varies significantly across different regions: the overall global prevalence of psoriasis ranges from 2.0% to 3.0%, while in China it is 0.47%. According to data released by the World Psoriasis Day Consortium, the total number of patients with psoriasis worldwide is approximately 125 million, and shows a year-on-year increasing trend. Psoriasis can be accompanied by other systemic abnormalities, patients with moderate-to-severe psoriasis have an increased risk of developing metabolic syndrome and atherosclerotic cardiovascular disease. Mental health conditions such as depression, anxiety, and suicidal tendencies caused by physical and psychological distress are also relatively common among the patients with psoriasis. Therefore, psoriasis is a disease that seriously affects the physical a...

More updates from Shanghai Junshi Biosciences Co., Ltd. Class A